Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
Abstract Pancreatic ductal adenocarcinoma (PDAC) is an aggressive and lethal malignancy with a high rate of recurrence and a dismal 5‐year survival rate. Contributing to the poor prognosis of PDAC is the lack of early detection, a complex network of signaling pathways and molecular mechanisms, a den...
Saved in:
Main Authors: | Heng‐Chung Kung, Jun Yu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-04-01
|
Series: | MedComm |
Subjects: | |
Online Access: | https://doi.org/10.1002/mco2.216 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Microbiome in pancreatic cancer – What is new in 2024?
by: E. Hohmann, et al.
Published: (2024-10-01) -
Prognostic significance of ımmunhistochemical axl expression in pancreas ductal adenocarcinomas
by: Ozden Oz, et al.
Published: (2023-07-01) -
Diagnostic and therapeutic recommendations in pancreatic ductal adenocarcinoma. Recommendations of the Working Group of the Polish Pancreatic Club
by: Katarzyna Winter, et al.
Published: (2019-03-01) -
CASC8 activates the pentose phosphate pathway to inhibit disulfidptosis in pancreatic ductal adenocarcinoma though the c-Myc-GLUT1 axis
by: Hong-Fei Yao, et al.
Published: (2025-01-01) -
FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival
by: Nathalie B. Rasko, et al.
Published: (2025-01-01)